ERBB2 and cancer: While high homogeneity rates had been found for loss of mismatch repair genes across several tumor entities including colorectal neuroendocrine carcinomas18, ovarian16, pancreatic15, and prostate cancer17, heterogeneity for HER2 amplification depends on the cancer type.